Urologic Oncology: From Diagnosis to Treatment
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".
Deadline for manuscript submissions: 15 March 2026 | Viewed by 18
Special Issue Editors
Interests: prostate cancer; kidney cancer; bladder cancer; testicular cancer; benign prostatic hyperplasia
Special Issue Information
Dear Colleagues,
Advances in diagnostic imaging, molecular and genomic profiling, and minimally invasive techniques have significantly enhanced our ability to detect, characterize, and treat genitourinary malignancies. Cancers of the prostate, bladder, kidney, and testis—which once relied on limited diagnostic and therapeutic strategies—are now managed with precision-based approaches, improving both oncological control and quality of life. Robotic-assisted surgery and advanced ablative technologies are redefining surgical standards, while immunotherapy and targeted agents are transforming systemic treatment paradigms. These developments have broadened therapeutic options, enabling tailored strategies for individual patients. However, they also present new challenges regarding optimal patient selection, long-term outcomes, and integration into clinical practice. In this Special Issue, we invite contributions encompassing original studies, clinical series, and review articles that highlight innovations in diagnostics, surgical techniques, systemic therapies, and the multidisciplinary management of urological cancers. Our aim is to provide a comprehensive overview of the evolving field of urological oncology and to stimulate a discussion on how these advances can best be translated into everyday practice.
Dr. Matteo Vittori
Dr. Valerio Iacovelli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- kidney cancer
- bladder cancer
- testicular cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
